Yousif Capital Management LLC lifted its holdings in IQVIA Holdings Inc. (NYSE:IQV – Get Rating) by 7.3% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 31,129 shares of the medical research company’s stock after acquiring an additional 2,110 shares during the quarter. Yousif Capital Management LLC’s holdings in IQVIA were worth $6,378,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Wedmont Private Capital boosted its stake in shares of IQVIA by 28.7% in the 4th quarter. Wedmont Private Capital now owns 1,842 shares of the medical research company’s stock worth $378,000 after buying an additional 411 shares during the last quarter. Symmetry Partners LLC raised its holdings in IQVIA by 14.8% during the 4th quarter. Symmetry Partners LLC now owns 2,244 shares of the medical research company’s stock valued at $460,000 after acquiring an additional 290 shares during the period. General Partner Inc. bought a new stake in IQVIA during the 4th quarter valued at $90,000. Centaurus Financial Inc. bought a new position in shares of IQVIA in the third quarter worth $403,000. Finally, Robeco Institutional Asset Management B.V. increased its holdings in shares of IQVIA by 4.4% in the third quarter. Robeco Institutional Asset Management B.V. now owns 349,061 shares of the medical research company’s stock worth $63,227,000 after purchasing an additional 14,717 shares during the period. Hedge funds and other institutional investors own 86.20% of the company’s stock.
Insiders Place Their Bets
In other news, insider Kevin C. Knightly sold 4,446 shares of the stock in a transaction that occurred on Thursday, February 16th. The stock was sold at an average price of $225.61, for a total transaction of $1,003,062.06. Following the completion of the transaction, the insider now directly owns 1,973 shares in the company, valued at approximately $445,128.53. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In other IQVIA news, insider Eric Sherbet sold 1,000 shares of the stock in a transaction on Tuesday, February 14th. The stock was sold at an average price of $230.00, for a total value of $230,000.00. Following the sale, the insider now directly owns 17,053 shares of the company’s stock, valued at $3,922,190. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Kevin C. Knightly sold 4,446 shares of the firm’s stock in a transaction on Thursday, February 16th. The shares were sold at an average price of $225.61, for a total value of $1,003,062.06. Following the transaction, the insider now directly owns 1,973 shares in the company, valued at $445,128.53. The disclosure for this sale can be found here. 1.50% of the stock is owned by company insiders.
Analysts Set New Price Targets
IQVIA Price Performance
IQVIA stock opened at $190.89 on Friday. The firm has a market capitalization of $35.53 billion, a PE ratio of 33.43, a P/E/G ratio of 1.97 and a beta of 1.40. The company has a quick ratio of 0.89, a current ratio of 0.89 and a debt-to-equity ratio of 2.18. The firm’s 50-day simple moving average is $218.94 and its 200 day simple moving average is $208.72. IQVIA Holdings Inc. has a 52 week low of $165.75 and a 52 week high of $254.94.
IQVIA (NYSE:IQV – Get Rating) last posted its quarterly earnings data on Friday, February 10th. The medical research company reported $2.78 EPS for the quarter, beating analysts’ consensus estimates of $2.76 by $0.02. The company had revenue of $3.74 billion during the quarter, compared to the consensus estimate of $3.71 billion. IQVIA had a net margin of 7.57% and a return on equity of 31.88%. The company’s quarterly revenue was up 2.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.42 EPS. On average, equities research analysts predict that IQVIA Holdings Inc. will post 9.46 EPS for the current fiscal year.
IQVIA Holdings, Inc engages in the provision of analytics, technology solutions, and clinical research services to the life sciences industry. It operates through the following segments: Technology and Analytics Solutions, Research and Development Solutions, and Contract Sales and Medical Solutions. The Technology and Analytics Solutions segment supplies mission critical information, technology solutions, and real-world solutions and services to the firm’s life science clients.
- Get a free copy of the StockNews.com research report on IQVIA (IQV)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV – Get Rating).
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.